KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Non Operating Income (2018 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Non Operating Income for 10 consecutive years, with $88.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 100.0% to $88.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, up 16.5% year-over-year, with the annual reading at -$2.6 million for FY2025, 16.5% up from the prior year.
  • Non Operating Income hit $88.0 in Q4 2025 for Inovio Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $185281.0 in Q2 2021 to a low of -$2.8 million in Q4 2022.
  • Historically, Non Operating Income has averaged -$701766.7 across 5 years, with a median of -$366643.5 in 2022.
  • Biggest five-year swings in Non Operating Income: surged 1799.44% in 2021 and later crashed 46746.03% in 2023.
  • Year by year, Non Operating Income stood at $177598.0 in 2021, then crashed by 1656.49% to -$2.8 million in 2022, then soared by 68.86% to -$860908.0 in 2023, then plummeted by 121.77% to -$1.9 million in 2024, then skyrocketed by 100.0% to $88.0 in 2025.
  • Business Quant data shows Non Operating Income for INO at $88.0 in Q4 2025, -$1.9 million in Q3 2025, and -$703183.0 in Q2 2025.